,address1,city,state,zip,country,phone,fax,website,industry,sector,longBusinessSummary,fullTimeEmployees,companyOfficers,auditRisk,boardRisk,compensationRisk,shareHolderRightsRisk,overallRisk,governanceEpochDate,compensationAsOfEpochDate,maxAge,priceHint,previousClose,open,dayLow,dayHigh,regularMarketPreviousClose,regularMarketOpen,regularMarketDayLow,regularMarketDayHigh,payoutRatio,beta,trailingPE,forwardPE,volume,regularMarketVolume,averageVolume,averageVolume10days,averageDailyVolume10Day,bid,ask,bidSize,askSize,marketCap,fiftyTwoWeekLow,fiftyTwoWeekHigh,priceToSalesTrailing12Months,fiftyDayAverage,twoHundredDayAverage,trailingAnnualDividendRate,trailingAnnualDividendYield,currency,enterpriseValue,profitMargins,floatShares,sharesOutstanding,sharesShort,sharesShortPriorMonth,sharesShortPreviousMonthDate,dateShortInterest,sharesPercentSharesOut,heldPercentInsiders,heldPercentInstitutions,shortRatio,shortPercentOfFloat,bookValue,priceToBook,lastFiscalYearEnd,nextFiscalYearEnd,mostRecentQuarter,netIncomeToCommon,trailingEps,forwardEps,pegRatio,enterpriseToRevenue,enterpriseToEbitda,exchange,quoteType,symbol,underlyingSymbol,shortName,longName,firstTradeDateEpochUtc,timeZoneFullName,timeZoneShortName,gmtOffSetMilliseconds,currentPrice,targetHighPrice,targetLowPrice,targetMeanPrice,targetMedianPrice,recommendationMean,recommendationKey,numberOfAnalystOpinions,totalCash,totalCashPerShare,ebitda,totalDebt,quickRatio,currentRatio,totalRevenue,debtToEquity,revenuePerShare,returnOnAssets,returnOnEquity,grossProfits,freeCashflow,operatingCashflow,revenueGrowth,grossMargins,ebitdaMargins,operatingMargins,financialCurrency,trailingPegRatio
0,9704 Medical Center Drive,Rockville,MD,20850,United States,301 251 5172,301 251 5321,https://www.macrogenics.com,Biotechnology,Healthcare,"MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3;Retifanlimab, an monoclonal antibody used for cancer therapeutics; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.",357,"{'maxAge': 1, 'name': 'Dr. Scott  Koenig M.D., Ph.D.', 'age': 70, 'title': 'Pres, CEO & Director', 'yearBorn': 1952, 'fiscalYear': 2022, 'totalPay': 1059292, 'exercisedValue': 0, 'unexercisedValue': 0}",7,4,6,7,6,1693526400,1672444800,86400,4,4.85,4.88,4.64,4.89,4.85,4.88,4.64,4.89,0.0,1.984785,38.833332,-2.089686,505826,505826,541827,561670,561670,4.6,4.67,1100,800,288684672,2.935,7.9,1.893449,5.0324,5.834325,0.0,0.0,USD,100002400,0.048860002,54608461,61949500,4950663,5600551,1690761600,1693440000,0.0799,0.026870001,0.94638,8.48,0.097600006,2.77,1.6823105,1672444800,1703980800,1688083200,7449000,0.12,-2.23,0.09,0.656,-1.184,NMS,EQUITY,MGNX,MGNX,"MacroGenics, Inc.","MacroGenics, Inc.",1381411800,America/New_York,EDT,-14400000,4.66,17.0,7.0,12.38,12.0,2.0,buy,8,240347008,3.88,-84490000,34319000,5.465,5.64,152464992,20.006,2.472,-0.23,0.04744,-62469000,-17381750,4976000,-0.495,-0.2631,-0.55416,-0.63201,USD,
1,9704 Medical Center Drive,Rockville,MD,20850,United States,301 251 5172,301 251 5321,https://www.macrogenics.com,Biotechnology,Healthcare,"MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3;Retifanlimab, an monoclonal antibody used for cancer therapeutics; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.",357,"{'maxAge': 1, 'name': 'Mr. James  Karrels', 'age': 55, 'title': 'Sr. VP, CFO & Corp. Sec.', 'yearBorn': 1967, 'fiscalYear': 2022, 'totalPay': 626829, 'exercisedValue': 0, 'unexercisedValue': 0}",7,4,6,7,6,1693526400,1672444800,86400,4,4.85,4.88,4.64,4.89,4.85,4.88,4.64,4.89,0.0,1.984785,38.833332,-2.089686,505826,505826,541827,561670,561670,4.6,4.67,1100,800,288684672,2.935,7.9,1.893449,5.0324,5.834325,0.0,0.0,USD,100002400,0.048860002,54608461,61949500,4950663,5600551,1690761600,1693440000,0.0799,0.026870001,0.94638,8.48,0.097600006,2.77,1.6823105,1672444800,1703980800,1688083200,7449000,0.12,-2.23,0.09,0.656,-1.184,NMS,EQUITY,MGNX,MGNX,"MacroGenics, Inc.","MacroGenics, Inc.",1381411800,America/New_York,EDT,-14400000,4.66,17.0,7.0,12.38,12.0,2.0,buy,8,240347008,3.88,-84490000,34319000,5.465,5.64,152464992,20.006,2.472,-0.23,0.04744,-62469000,-17381750,4976000,-0.495,-0.2631,-0.55416,-0.63201,USD,
2,9704 Medical Center Drive,Rockville,MD,20850,United States,301 251 5172,301 251 5321,https://www.macrogenics.com,Biotechnology,Healthcare,"MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3;Retifanlimab, an monoclonal antibody used for cancer therapeutics; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.",357,"{'maxAge': 1, 'name': 'Mr. Eric Blasius Risser', 'age': 49, 'title': 'Chief Operating Officer', 'yearBorn': 1973, 'fiscalYear': 2022, 'totalPay': 651362, 'exercisedValue': 0, 'unexercisedValue': 0}",7,4,6,7,6,1693526400,1672444800,86400,4,4.85,4.88,4.64,4.89,4.85,4.88,4.64,4.89,0.0,1.984785,38.833332,-2.089686,505826,505826,541827,561670,561670,4.6,4.67,1100,800,288684672,2.935,7.9,1.893449,5.0324,5.834325,0.0,0.0,USD,100002400,0.048860002,54608461,61949500,4950663,5600551,1690761600,1693440000,0.0799,0.026870001,0.94638,8.48,0.097600006,2.77,1.6823105,1672444800,1703980800,1688083200,7449000,0.12,-2.23,0.09,0.656,-1.184,NMS,EQUITY,MGNX,MGNX,"MacroGenics, Inc.","MacroGenics, Inc.",1381411800,America/New_York,EDT,-14400000,4.66,17.0,7.0,12.38,12.0,2.0,buy,8,240347008,3.88,-84490000,34319000,5.465,5.64,152464992,20.006,2.472,-0.23,0.04744,-62469000,-17381750,4976000,-0.495,-0.2631,-0.55416,-0.63201,USD,
3,9704 Medical Center Drive,Rockville,MD,20850,United States,301 251 5172,301 251 5321,https://www.macrogenics.com,Biotechnology,Healthcare,"MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3;Retifanlimab, an monoclonal antibody used for cancer therapeutics; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.",357,"{'maxAge': 1, 'name': 'Dr. Thomas M. Spitznagel Ph.D.', 'age': 55, 'title': 'Sr. VP of Technical Operations', 'yearBorn': 1967, 'fiscalYear': 2021, 'exercisedValue': 0, 'unexercisedValue': 0}",7,4,6,7,6,1693526400,1672444800,86400,4,4.85,4.88,4.64,4.89,4.85,4.88,4.64,4.89,0.0,1.984785,38.833332,-2.089686,505826,505826,541827,561670,561670,4.6,4.67,1100,800,288684672,2.935,7.9,1.893449,5.0324,5.834325,0.0,0.0,USD,100002400,0.048860002,54608461,61949500,4950663,5600551,1690761600,1693440000,0.0799,0.026870001,0.94638,8.48,0.097600006,2.77,1.6823105,1672444800,1703980800,1688083200,7449000,0.12,-2.23,0.09,0.656,-1.184,NMS,EQUITY,MGNX,MGNX,"MacroGenics, Inc.","MacroGenics, Inc.",1381411800,America/New_York,EDT,-14400000,4.66,17.0,7.0,12.38,12.0,2.0,buy,8,240347008,3.88,-84490000,34319000,5.465,5.64,152464992,20.006,2.472,-0.23,0.04744,-62469000,-17381750,4976000,-0.495,-0.2631,-0.55416,-0.63201,USD,
4,9704 Medical Center Drive,Rockville,MD,20850,United States,301 251 5172,301 251 5321,https://www.macrogenics.com,Biotechnology,Healthcare,"MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3;Retifanlimab, an monoclonal antibody used for cancer therapeutics; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.",357,"{'maxAge': 1, 'name': 'Dr. Ezio  Bonvini', 'age': 68, 'title': 'Sr. VP of Research & Chief Scientific Officer', 'yearBorn': 1954, 'fiscalYear': 2021, 'exercisedValue': 0, 'unexercisedValue': 0}",7,4,6,7,6,1693526400,1672444800,86400,4,4.85,4.88,4.64,4.89,4.85,4.88,4.64,4.89,0.0,1.984785,38.833332,-2.089686,505826,505826,541827,561670,561670,4.6,4.67,1100,800,288684672,2.935,7.9,1.893449,5.0324,5.834325,0.0,0.0,USD,100002400,0.048860002,54608461,61949500,4950663,5600551,1690761600,1693440000,0.0799,0.026870001,0.94638,8.48,0.097600006,2.77,1.6823105,1672444800,1703980800,1688083200,7449000,0.12,-2.23,0.09,0.656,-1.184,NMS,EQUITY,MGNX,MGNX,"MacroGenics, Inc.","MacroGenics, Inc.",1381411800,America/New_York,EDT,-14400000,4.66,17.0,7.0,12.38,12.0,2.0,buy,8,240347008,3.88,-84490000,34319000,5.465,5.64,152464992,20.006,2.472,-0.23,0.04744,-62469000,-17381750,4976000,-0.495,-0.2631,-0.55416,-0.63201,USD,
5,9704 Medical Center Drive,Rockville,MD,20850,United States,301 251 5172,301 251 5321,https://www.macrogenics.com,Biotechnology,Healthcare,"MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3;Retifanlimab, an monoclonal antibody used for cancer therapeutics; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.",357,"{'maxAge': 1, 'name': 'Mr. Jeffrey Stuart Peters', 'age': 51, 'title': 'Sr. VP, Gen. Counsel & Corp. Compliance Officer', 'yearBorn': 1971, 'exercisedValue': 0, 'unexercisedValue': 0}",7,4,6,7,6,1693526400,1672444800,86400,4,4.85,4.88,4.64,4.89,4.85,4.88,4.64,4.89,0.0,1.984785,38.833332,-2.089686,505826,505826,541827,561670,561670,4.6,4.67,1100,800,288684672,2.935,7.9,1.893449,5.0324,5.834325,0.0,0.0,USD,100002400,0.048860002,54608461,61949500,4950663,5600551,1690761600,1693440000,0.0799,0.026870001,0.94638,8.48,0.097600006,2.77,1.6823105,1672444800,1703980800,1688083200,7449000,0.12,-2.23,0.09,0.656,-1.184,NMS,EQUITY,MGNX,MGNX,"MacroGenics, Inc.","MacroGenics, Inc.",1381411800,America/New_York,EDT,-14400000,4.66,17.0,7.0,12.38,12.0,2.0,buy,8,240347008,3.88,-84490000,34319000,5.465,5.64,152464992,20.006,2.472,-0.23,0.04744,-62469000,-17381750,4976000,-0.495,-0.2631,-0.55416,-0.63201,USD,
6,9704 Medical Center Drive,Rockville,MD,20850,United States,301 251 5172,301 251 5321,https://www.macrogenics.com,Biotechnology,Healthcare,"MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3;Retifanlimab, an monoclonal antibody used for cancer therapeutics; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.",357,"{'maxAge': 1, 'name': 'Dr. Stephen L. Eck M.D., Ph.D.', 'age': 67, 'title': 'Sr. VP of Clinical Devel. & Chief Medical Officer', 'yearBorn': 1955, 'fiscalYear': 2020, 'exercisedValue': 0, 'unexercisedValue': 0}",7,4,6,7,6,1693526400,1672444800,86400,4,4.85,4.88,4.64,4.89,4.85,4.88,4.64,4.89,0.0,1.984785,38.833332,-2.089686,505826,505826,541827,561670,561670,4.6,4.67,1100,800,288684672,2.935,7.9,1.893449,5.0324,5.834325,0.0,0.0,USD,100002400,0.048860002,54608461,61949500,4950663,5600551,1690761600,1693440000,0.0799,0.026870001,0.94638,8.48,0.097600006,2.77,1.6823105,1672444800,1703980800,1688083200,7449000,0.12,-2.23,0.09,0.656,-1.184,NMS,EQUITY,MGNX,MGNX,"MacroGenics, Inc.","MacroGenics, Inc.",1381411800,America/New_York,EDT,-14400000,4.66,17.0,7.0,12.38,12.0,2.0,buy,8,240347008,3.88,-84490000,34319000,5.465,5.64,152464992,20.006,2.472,-0.23,0.04744,-62469000,-17381750,4976000,-0.495,-0.2631,-0.55416,-0.63201,USD,
7,9704 Medical Center Drive,Rockville,MD,20850,United States,301 251 5172,301 251 5321,https://www.macrogenics.com,Biotechnology,Healthcare,"MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3;Retifanlimab, an monoclonal antibody used for cancer therapeutics; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.",357,"{'maxAge': 1, 'name': 'Ms. Lynn  Cilinski', 'age': 64, 'title': 'VP, Controller & Treasurer', 'yearBorn': 1958, 'exercisedValue': 0, 'unexercisedValue': 0}",7,4,6,7,6,1693526400,1672444800,86400,4,4.85,4.88,4.64,4.89,4.85,4.88,4.64,4.89,0.0,1.984785,38.833332,-2.089686,505826,505826,541827,561670,561670,4.6,4.67,1100,800,288684672,2.935,7.9,1.893449,5.0324,5.834325,0.0,0.0,USD,100002400,0.048860002,54608461,61949500,4950663,5600551,1690761600,1693440000,0.0799,0.026870001,0.94638,8.48,0.097600006,2.77,1.6823105,1672444800,1703980800,1688083200,7449000,0.12,-2.23,0.09,0.656,-1.184,NMS,EQUITY,MGNX,MGNX,"MacroGenics, Inc.","MacroGenics, Inc.",1381411800,America/New_York,EDT,-14400000,4.66,17.0,7.0,12.38,12.0,2.0,buy,8,240347008,3.88,-84490000,34319000,5.465,5.64,152464992,20.006,2.472,-0.23,0.04744,-62469000,-17381750,4976000,-0.495,-0.2631,-0.55416,-0.63201,USD,
